P1077FF: Formula Feeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)

Study Location:



HIVMaternal-Child Health and HIV

Clinicaltrials.gov Link:





Nishi Suryavanshi



Trial Period:


1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting Maternal and Infant Survival Everywhere (PROMISE) Protocol is a research protocol of the IMPAACT network designed to address in an integrated and comprehensive fashion critical questions currently facing HIV-infected pregnant and postpartum women and their infants:

What is the optimal intervention for the prevention of antepartum and intrapartum transmission of HIV?
What is the optimal intervention for the preservation of maternal health after the risk period for prevention of mother-to-child-transmission ends (either at delivery or cessation of BF)?

This version of the PROMISE protocol (IMPAACT 1077FF) is intended for those sites where the standard method of infant feeding is formula feeding.

Antepartum Component – HIV-infected pregnant women who intend to formula feed (FF) (with and without HBV) with documented CD4 cell count > 350 cells/mm3 at screening, enrolled from 14 weeks gestation forward and prior to the onset of labor, who are ARV-naïve except for ARVs given for prior PMTCT in previous pregnancies, and their infants.

Maternal Health Component - The study population will include consenting, eligible HIV-infected women with a CD4 count of ≥ 350 cells/mm3 who were randomized to triple ARV prophylaxis in the Antepartum Component and who are formula-feeding their infants. Another comparison group will be women who did not receive triple ARV prophylaxis during pregnancy (i.e., women randomized to Antepartum ZDV + sdNVP + TRV tail) and who are formula-feeding their infants.



Clinical Trials

P1077BF: Breastfeeding Version of the PROMISE Study...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

A5346: Sitagliptin for Reducing Inflammation and Immune...

The purpose of the study is to evaluate whether sitagliptin (Januvia is the brand name for sitagliptin)...

Read More

A5361s: Pitavastatin to REduce Physical Function Impairment...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

A5320: Viral Hepatitis C Infection Long-term Cohort Study...

A5320/V-HICS is an observational, prospective, long-term follow-up study in hepatitis C virus (HCV) monoinfected and HCV/HIV-1...

Read More